ramucirumab,pembrolizumab
eli lilly,merck
['s1800a', 'sclc', 'nsclc', 'ramucirumab', 'pembrolizumab']
s1800a randomized phase ii trial comparing pembrolizumab + ramucirumab vs. soc in nsclc previously treated with io &amp; chemo by soc group mostly received doce + ram mos 14.5 vs. 11.6 months favoring pembro+ram exciting results that warrant further evaluation #asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM